P3I
ABVX

Progeny 3 Inc’s Abivax ABVX Stock Holding History

Progeny 3 Inc’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,240
Closed -$1.36M – 30
2026
Q1 		$1.36M Hold
12,240
– – 0.07% 29
2025
Q4 		$1.65M Hold
12,240
– – 0.09% 32
2025
Q3 		$1.04M Buy
+12,240
New +$750K 0.05% 34

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Progeny 3 Inc's ABVX Position: Q2 2026 in Review

Progeny 3 Inc sold out of Abivax (ABVX) in Q2 2026, closing a stake of 12,240 shares — an estimated $1.36M sold.

Progeny 3 Inc first reported a position in ABVX in Q3 2025 and held it in 3 quarters. The position peaked at $1.65M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Progeny 3 Inc reported no remaining Abivax position as of Q2 2026 after selling out during the quarter.
  • Progeny 3 Inc sold 12,240 Abivax shares in Q2 2026, an estimated $1.36M.
  • Progeny 3 Inc first reported a position in Abivax in Q3 2025 and held it in 3 quarters.
  • Progeny 3 Inc's Abivax position peaked at $1.65M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Progeny 3 Inc's 13F filing for Q2 2026, filed 14 Aug 2026.